Video

Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Rituximab in combination with bortezomib and rituximab in combination with lenalidomide have shown success for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma . Both combinations provide a fairly high response rate in both the frontline setting and the relapse setting, says Ma.

B-cell receptor pathway inhibitors including ibrutinib and idelalisib also offer exciting benefits. Both have shown significant activity across many different forms of b-cell malignancies.

<<<

View more from the 2015 Congress on Hematologic Malignancies

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO